Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C19H21NO2 |
| Molecular Weight | 295.3755 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC2=C3[C@@H](CC4=C(C=CC=C4)C3=C1OC)N(C)CC2
InChI
InChIKey=ORJVQPIHKOARKV-OAHLLOKOSA-N
InChI=1S/C19H21NO2/c1-20-9-8-13-11-16(21-2)19(22-3)18-14-7-5-4-6-12(14)10-15(20)17(13)18/h4-7,11,15H,8-10H2,1-3H3/t15-/m1/s1
| Molecular Formula | C19H21NO2 |
| Molecular Weight | 295.3755 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Nuciferine is an aporphine alkaloid extracted from lotus leaves, which is a raw material in Chinese medicinal herb for weight loss. Nuciferine was studied as an anti-tumor agent against human neuroblastoma and mouse colorectal cancer, through inhibiting the PI3K-AKT signaling pathways and IL-1 levels. In addition, was suggested, that nuciferine had atypical antipsychotic-like actions. Nuciferine was an antagonist at 5-HT2A, 5-HT2C, and 5-HT2B, an inverse agonist at 5-HT7, a partial agonist at D2, D5 and 5-HT6, an agonist at 5-HT1A and D4 receptors, and inhibited the dopamine transporter. In addition, was shown, that that nuciferine had a therapeutic effect on respiratory diseases associated with the aberrant contraction of airway smooth muscles and/or bronchospasm through the blockade of voltage-dependent L-type Ca2+ channels and/or nonselective cation channels.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26770351
Curator's Comment: Known to be CNS penetrant in rat. Human data not available
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: map04151 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27180984 |
|||
Target ID: CHEMBL2095200 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26963248 |
|||
Target ID: Q01959 Gene ID: 6531.0 Gene Symbol: SLC6A3 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/26963248 |
|||
Target ID: P08908 Gene ID: 3350.0 Gene Symbol: HTR1A Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/26963248 |
3.2 µM [EC50] | ||
Target ID: P34969 Gene ID: 3363.0 Gene Symbol: HTR7 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/26963248 |
150.0 nM [IC50] | ||
Target ID: CHEMBL2095229 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28817840 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Identification of the anti-tumor activity and mechanisms of nuciferine through a network pharmacology approach. | 2016-07 |
|
| In Vitro and In Vivo Characterization of the Alkaloid Nuciferine. | 2016 |
|
| Antipoliovirus structure-activity relationships of some aporphine alkaloids. | 1998-04 |
|
| Psychopharmacological studies on (--)-nuciferine and its Hofmann degradation product atherosperminine. | 1978-09-15 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27180984
tumor-bearing mice: Mice in the nuciferine (1) group were immediately administered nuciferine (ip) after tumor implantation, and mice in the nuciferine (2) group were administered nuciferine (ip) when the tumor xenografts reached a size of 100 mm3. Mice in the nuciferine (1) group and nuciferine (2) group were administered nuciferine (ip) three times a week at a dosage of 9.5 mg/kg.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27180984
Cells (A549, NCI-H1650, HT29, CT26, HCT116 and SY5Y) were treated with nuciferine (0, 0.05, 0.1, 0.2, 0.4, 0.8, and 1.0 mg/mL) for 24 h. Nuciferine, at 0.8 mg/mL, elicited a more significant inhibitory effect on the proliferation of CT26 and SY5Y cells than on other cancer cells.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 21:49:58 GMT 2025
by
admin
on
Mon Mar 31 21:49:58 GMT 2025
|
| Record UNII |
W26UEB90B7
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID40963862
Created by
admin on Mon Mar 31 21:49:58 GMT 2025 , Edited by admin on Mon Mar 31 21:49:58 GMT 2025
|
PRIMARY | |||
|
W26UEB90B7
Created by
admin on Mon Mar 31 21:49:58 GMT 2025 , Edited by admin on Mon Mar 31 21:49:58 GMT 2025
|
PRIMARY | |||
|
475-83-2
Created by
admin on Mon Mar 31 21:49:58 GMT 2025 , Edited by admin on Mon Mar 31 21:49:58 GMT 2025
|
PRIMARY | |||
|
10146
Created by
admin on Mon Mar 31 21:49:58 GMT 2025 , Edited by admin on Mon Mar 31 21:49:58 GMT 2025
|
PRIMARY | |||
|
Nuciferine
Created by
admin on Mon Mar 31 21:49:58 GMT 2025 , Edited by admin on Mon Mar 31 21:49:58 GMT 2025
|
PRIMARY | |||
|
W26UEB90B7
Created by
admin on Mon Mar 31 21:49:58 GMT 2025 , Edited by admin on Mon Mar 31 21:49:58 GMT 2025
|
PRIMARY |